European Commission approval of ICOTYDE™▼(icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Johnson & Johnson introduces the first IL-23R targeted oral peptide that can deliver skin clearance and a favourable safety profile in a once-daily pill.^1,2